Clinical Trial: To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090759) titled 'To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment' on July 15.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GST-HG141 in patients with chronic hepatitis B who have an inadequate response to antiviral drug treatment.

Study Start Date: Sept. 13

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis b

Intervention: DRUG: GST-HG141

GST-HG141 50 mg BID

DRUG: GST-HG141 Placebo

GST-HG141...